Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (121-130 of 277) with videos related to

Pageof 28
Sort By:
The Lancet. Oncology|April 22, 2014
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyDavid S Hong, David Hui, Eduardo Bruera, et al.
Anticancer Research|April 30, 2014
Outcomes of patients with metastatic cervical cancer in a phase I clinical trials programMing-Mo Hou, Xiaochun Liu, Jennifer Wheler, et al.
Investigational New Drugs|June 13, 2013
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancerPrasanth Ganesan, Sarina Piha-Paul, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology|July 18, 2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2018
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.
Investigational New Drugs|November 4, 2014
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.
Oncotarget|July 9, 2014
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester diseaseFilip Janku, Cecile Rose T Vibat, Karena Kosco, et al.
Scientific Reports|February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignanciesYudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Pageof 28

Showing results (121-130 of 277) with videos related to

Sort By:
Pageof 28
The Lancet. Oncology|April 22, 2014
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyDavid S Hong, David Hui, Eduardo Bruera, et al.
Anticancer Research|April 30, 2014
Outcomes of patients with metastatic cervical cancer in a phase I clinical trials programMing-Mo Hou, Xiaochun Liu, Jennifer Wheler, et al.
Investigational New Drugs|June 13, 2013
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancerPrasanth Ganesan, Sarina Piha-Paul, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology|July 18, 2018
Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2018
A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancerAmita Patnaik, Michael Gordon, Frank Tsai, et al.
Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.
Investigational New Drugs|November 4, 2014
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.
Oncotarget|July 9, 2014
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester diseaseFilip Janku, Cecile Rose T Vibat, Karena Kosco, et al.
Scientific Reports|February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignanciesYudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Pageof 28